ESSENCE project – Drug Development With Neuronal Stem Cells On Neurochips
Dr. Olaf Schröder, CEO of NeuroProof GmbH, made the following statement on the project: “We are looking forward to embarking on the ESSENCE project with a group of highly competent partners. The opportunity to cultivate human neuronal cells on our MEA neurochips may allow us to improve the predictability of the effect of new substances in the treatment of serious diseases of the central nervous system in unforeseen ways. This will allow our pharmaceutical industry customers to accurately judge the potential of their candidates for development at a much earlier stage.”
The aim of the project is to be able to predict the effect of drugs or potentially toxic substances more accurately and reliably using the in-vitro test procedure. This will help significantly to reduce the unimaginably high costs of developing central nervous system drugs, of which only one in ten actually passes clinical trials, and in the end will lead to the more rapid availability of more effective drugs.
The 1.5 million Euro project is set to run for three years and is funded by the Eurotransbio (ETB) initiative as part of the European Commission’s ERA-NET scheme.